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Summary We sought to determine whether women with in situ or invasive squamous cell vulvar cancer were
more likely than other women to have had a previous or concurrent tumour at other anogenital sites. One
hundred and fifty-eight women with vulvar cancer were identified who were first diagnosed during 1980-1985,
were ages 18-79 years at that time, and were residents of one of three counties in western Washington. Two
control groups were selected: (1) from records of hospital pathology departments, a sample of 113 women
with certain benign conditions of the vulva; (2) through random digit dialing, a sample of 212 women from
the general population of these counties. Information on a history of other cancers, and on sexual,
reproductive, medical, and demographic characteristics was collected from cases and controls in at-home
interviews. Cases were more likely to report a history of other anogenital cancers than were controls, with
relative risks of 3.5-29.8, depending on the type of case group and type of control. These associations were
not explained by case-control differences in demographic characteristics or frequency of cervical screening. On
the other hand, prior or concurrent non-anogenital cancers were equally common in cases and controls. These
results support the hypothesis that the different anogenital cancers have at least one aetiology in common.
Recent research suggests that cancers of the cervix, vulva,
and anus may share one or more risk factors (Peters et al.,
1984; Okagaki, 1984). If this is true, women with cancer at
one anogenital site would be at increased risk of developing
another anogenital tumour. One way to examine this possi-
bility is to see if women with cancer at a specific anogenital
site were more likely than other women to have had a
previous or concurrent tumour at another anogenital site.
There have been numerous reports of women with
squamous cell cancer of the vulva who have had one or
more second primary malignancies of the anogenital tract
(Taussig, 1940; Cromer, 1963; Day, 1958; Caberra et al.,
1966), especially the cervix (Franklin & Rutledge, 1974;
Friedrich et al., 1980), that were detected before (McPherson
et al., 1963), simultaneous with (Eichner, 1956), or after the
vulvar tumour (Diehl et al., 1951). While these reports are
intriguing, they were not derived from a defined population,
nor were the cases compared to a control group. Using data
on cancer incidence rates from the Connecticut Tumor
Registry, Schoenberg (1977) showed that women who had
cervical cancer were at greater risk for other anogenital
malignancies compared with other women. In a hospital-
based, case-control study of vulvar cancer, Mabuchi et al.
(1985) found that six of 149 women with vulvar cancer but none
of 149 controls had a history of prior urogenital cancer.
As part of a case-control study of women with in situ and
invasive vulvar cancer, we had the opportunity to examine
the hypothesis that multiple anogenital malignancies occur
more commonly that would be predicted by chance.
Patients and methods
With the assistance of the population-based cancer reporting
system in western Washington, we identified all women ages
18-79 years with in situ or invasive vulvar cancer who were
residents of King, Pierce, or Snohomish Counties and were
diagnosed during 1980-1985. All diagnoses were histo-
logically confirmed. Women were interviewed during 1984-
1987, after being approached by means of a letter from their
physicians. The response status of women with cancer (all
histologies) is shown in Table I. Only women with squamous
cell carcinoma of the vulva (91% of all interviewed cases)
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comprised the cases in this analysis. Among the interviewed
cases, a total of 123 women with in situ vulvar cancer and a
total of 35 women with invasive vulvar cancer met our
eligibility criteria.
Two separate control groups were selected: (1) women
with certain benign conditions of the vulva and (2) a random
sample of the population obtained by random digit dialing.
All hospital pathology departments and the major indepen-
dent pathology laboratories were contacted for permission to
abstract the names, ages, biopsy dates, and physicians for
women who were biopsied for benign vulvar conditions.
Virtually all (97%) of the pathology laboratories agreed to
participate. Only those diagnoses thought to be unrelated to
vulvar cancer and to condyloma acuminatum were
abstracted and used to select women for the 'biopsy' control
group. The majority of the 113 women in the 'biopsy'
control group had a diagnosis of nevi (28), inflammation
(12), epidermoid cyst (12), lentigo (10), fibroepithelial polyp
(8), skin tag (7), hydradenoma (6), abscess (4), or
haemangioma (3). The remaining 23 women in this control
group had one of 17 other diagnoses. Among 104 women
who reported why they visited a physician at the time the
biopsy was performed, most of the women stated that they
visited the physician for a routine exam or a pregnancy-
related exam (45) or because they were concerned about the
condition that was biopsied during their visit (33). Other
reasons women gave for that physician visit included com-
plaints associated with bleeding (7), other gynaecologic
problems (8), non-gynaecologic problems (6), and surgery for
non-gynaecologic conditions (5). This control group was
selected originally to provide tissue controls for another
aspect of this study. An attempt was made to match a
'biopsy' control to a case on the basis of diagnosis year,
county of residence, and age (5-year groups). Although we
were able to match on year and age, we found it difficult to
find matches for women from the two less urban counties in
our study and as a result, we did not find a match for 45
women. The controls we could identify were also approached
by means of a letter from their physician. Their response
status is shown in Table I. Most non-respondents were lost
to follow-up because they did not obtain regular care from
the physician who performed the biopsy and, often, so little
information about them was available that public records
could not be used successfully to trace them.
Using the method of Waksberg (1978), random digit
dialing was used to obtain the second control group, i.e., a
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sample of women from the population at large. These
women were frequency-matched to cases on county of
residence and age (5-year groups). A total of 2,571 telephone
numbers were dialed. For 3% of the phone numbers called,
we were unable to determine if they were residential or non-
residential. A household census was successfully conducted
for 95% of the residences called. Among the eligible women
for the study, 76% were interviewed.
The interview that was administered to both cases and
controls was structured and was conducted in person. It
included questions about sexual, reproductive, contraceptive,
and medical histories (including other cancers and sexually
transmitted diseases), demographic characteristics, Pap smear
history, and the use of tobacco, alcohol, and social drugs.
All information was collected only up to the date of
diagnosis of the case or a comparable time period for her
control. Women were asked about a history of all cancers,
including the anatomic site, age at diagnosis, type of treat-
ment, physician treating the cancer and the geographic area
where the diagnosis was made. For the purpose of these
analyses, diagnoses of prior or concurrent malignancy were
divided into two groups: anogenital cancers (cancers of the
cervix, vagina, anus) and other cancers. An earlier or
concurrent vulvar cancer was not included as an anogenital
cancer (no controls reported a history of vulvar cancer). For
some analyses, anogenital cancers were further classified into
concurrent tumours, e.g., those tumours diagnosed within
one year of the date the vulvar cancer was diagnosed (or the
vulvar biopsy was taken) and prior tumours, those tumours
diagnosed more than one year before the vulvar cancer
diagnosis.
Twelve women reported a history of uterine cancer. Eight
of these tumours were noted as either cervical or endometrial
in the Tumour Registry abstract, and this information was
used to classify these tumours as anogenital or other.
Because three of the four remaining women stated that their
tumour occurred before they were 30, it is likely that these
tumours were of the cervix, and thus should be considered
anogenital cancers. Several analyses were conducted
classifying these tumours as other, and the results were not
materially altered.
Relative risks were approximated by the odds ratio for
which the conditional maximum likelihood estimate was
computed. Exact confidence limits were calculated using the
algorithm of Mehta et al. (1986). Because all women with
invasive vulvar cancer were over 35 years of age, this group
of cases was compared only to those controls over the age of
35.
An attempt was made to assess the accuracy of a subject's
reported history of prior or concurrent cancer by examining
the records of the population-based SEER Tumour Registry.
These records include all individuals who had a diagnosis of
cancer (except basal and squamous cell skin cancer) in 13
counties of western Washington after 1973. In addition,
tumours diagnosed outside the geographic boundaries of the
Tumour Registry or before it began are recorded on the
Registry abstracts of cancer cases whenever this information
is available.
Twenty-nine of the 33 anogenital tumours that were
reported by the cases and three of seven reported by the
controls conformed to the conditions that were necessary for
verification using the records of the Tumour Registry. Of
those, 27 of 29 of the cases' tumours and two of three of the
controls' neoplasms had been identified in the records as
well. On the other hand, two cases and one RDD control
had prior tumours identified in the Registry records that
they did not report during the interview. For the purposes of
these analyses, only cancers reported by the subjects were
included.
Results
Table II presents some demographic characteristics of cases
Table I Response status of women with vulvar cancer
and biopsy controls
Casesa Controls
Response No. % No. %
Interviewed 174 67.2 113 59.8
Deceased 20 7.7 6 3.2
Physician refusal 8 3.1 10 5.3
Patient refusal 38 14.7 18 9.5
Too ill 4 1.5 5 2.7
Lost to follow up 15 5.8 37 19.6
aOnly 158 interviewed cases had squamous cell
carcinoma of the vulva, and the analyses included only
these cases.
and controls. Women with invasive vulvar cancer tended to
be older than those with in situ vulvar cancer. The age
distributions of the biopsy and RDD controls were more
similar to those of the women with in situ vulvar cancer. On
the average, cases reported less education and lower income
than either of the control groups. Biopsy controls were more
likely to have resided in King County than were cases or
RDD controls. Cases and controls were similarly distributed
in terms of race.
Women with in situ vulvar cancer reported a history of at
least one primary anogenital cancer (three of these cases
reported two anogenital cancers) at or before the reference
date more often than women in either control group (age-
adjusted OR=6.2, 95% CI=2.3-21.4, biopsy controls as
comparison; OR=29.8, 95% CI=7.3-263.4, RDD controls
as comparison, (Table III). Women with invasive vulvar
cancer had a similar excess (age-adjusted OR=3.5, 95%
CI=0.7-20.6, biopsy controls as comparison; OR= 19.1,
95% CI=2.7-228.9, RDD controls as comparison, (Table
III). Strong associations were present when prior and
concurrent tumours were examined separately (Table III).
Among the 19 women who were diagnosed with in situ
vulvar cancer who reported a prior anogenital tumour, an
average of 12 years elapsed between the diagnosis of the
anogenital and the vulvar tumours. Only 16% of these
women reported an interval of less than 5 years between the
two diagnoses, and 42% of the women reported an interval
of more than 10 years between tumours. All four women
who were diagnosed with invasive vulvar cancer and who
reported a prior anogenital tumour reported an interval of
more than 10 years between tumours. The majority (81%) of
these non-vulvar anogenital cancers were cervical tumours,
but there were also five anal and two vaginal cancers
reported.
These associations were not explained by case-control
differences in demographic characteristics. Adjusting
separately for education, income, reference year, and county
of residence altered the odds ratio only slightly. Because only
five biopsy controls and two RDD controls reported a
history of anogenital cancer, adjusting simultaneously for all
demographic differences between cases and controls was not
feasible.
The association between vulvar cancer and prior
anogenital tumours did not appear to be a consequence of
radiation treatment of the initial anogenital tumour. Only
four women reported treatment of their initial tumour by
radiation, and the magnitude of the association was
unaffected by the exclusion of these women.
Over 99% of all cases and controls reported having had a
Pap smear at least once. After adjusting for the average
interval between Pap smears during the ten years before
reference date (more than 5 years, between 1 and 5 years, 1
year or less), a strong association remained.
By contrast, there was no association between in situ or
invasive vulvar cancer and a history of prior or concurrent
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Table II Demographic characteristics of cases and controls
Biopsy RDD
In situ Invasive controls controls
N=123 % N=35 % N=113 % N=212 %
Age (years)
<40 52 42.3 3 8.6 44 38.9 76 35.8
40-59 39 31.7 9 25.7 38 33.6 74 34.9
60+ 32 26.0 23 65.7 31 27.4 62 29.2
Educationc
<High school 71 58.8 24 56.6 42 37.7 83 39.1
>High school 52 41.1 11 43.3 71 62.2 129 60.9
Annualfamily incomea,
<$15,000 54 44.9 17 42.3 28 25.6 58 27.6
$15,000-30,000 44 35.6 7 15.4 42 37.1 84 40.0
>$30,000 24 19.4 9 37.2 41 36.9 68 32.4
County ofresidencec
King 81 66.1 21 61.1 94 83.3 123 58.0
Pierce 20 16.6 8 17.9 12 10.7 51 24.1
Snohomish 22 17.3 6 20.9 7 6.0 38 17.9
Racec
White 119 96.5 32 93.5 109 96.6 194 91.5
Non-white 4 3.6 3 6.4 4 3.3 18 8.5
Frequency ofprior Pap smearbc
(within last 10 years)
<5 years 20 17.7 13 34.9 14 12.9 41 19.4
2-5 years 20 15.9 6 20.9 28 24.8 57 27.0
At least yearly 82 66.3 16 44.0 71 62.1 113 53.6
aOne in situ case, 1 invasive case, 2 biopsy controls and 2 RDD controls refused to answer this question. One
invasive case did not know the answer to this question; bOne in situ case and one RDD control did not know the
answer to this question; CAll of these percentages are adjusted to the age distribution of the RDD controls (18-39,
40-59, 60-79).
Table III Association between vulvar cancer and other primary tumours in womena
In situ! In situ! Invasivel Invasivel
Biopsy RDD Biopsy RDD
In situ Invasive Biopsy RDD RR RR RR RR
N=123 N=35 N=113 N=212 95% CI 95% CI 95% CI 95% CI
All with prior and/or current
anogenital cancers 6.2 29.8 3.5 19.1
28 22% 5 24.8% 5 4.6% 2 1% 2.3-21.4 7.3-263.2 0.7-20.6 2.7-228.9
Site:b
6.5 24.6 5.4 19.1
Cervical 24 18.8% 5 24.8% 4 3.6% 2 1% 2.1-26.5 5.9-281.5 0.9-40.3 2.7-228.9
6.7 c _ _
Other 7 5.4% 0 0% 1 0.9% 0 0% 0.8-307.3 3.2-oo - -
Timing:b
6.6 19.0 3.8 13.3
Prior 19 15.4% 4 12.9% 3 2.8% 2 1% 1.9-36.0 4.4-171.0 0.6-29.6 1.7-166.3
5.3 oo 2.4 co
Concurrent 11 8.2% 1 11.9% 2 1.8% 0 0% 1.1-50.6 5.5-oo 0.03-216.1 0.32-oo
All with prior and/or concurrent
non-anogenital cancers 0.97 0.7 1.0 0.9
7 6.4% 4 7.8% 7 6.5% 17 8.0% 0.3-3.5 0.2-1.8 0.2-4.5 0.2-3.0
'All percentages are age-adjusted to the distribution of the RDD population; all RRs are age-adjusted; bTwo in situ cases reported one prior
and one concurrent anogenital cancer; one in situ case reported two concurrent anogenital cancers.
majority of the other cancers were of the breast (N= 13),
skin (N= I 1), endometrium (N=5), and colon (N =2).
Discussion
We found that women with in situ or invasive vulvar cancer
reported a history of prior or concurrent anogenital tumours
far more often than did women in either control group. This
association is likely to be confined to squamous cell
tumours. Of the 16 women with non-squamous cell vulvar
tumours (these diagnoses included melanoma, basal cell
cancer, and Paget's disease), none reported a prior or
concurrent anogenital malignancy. The strong association of
anogenital tumours and squamous cell vulvar cancer, when
contrasted with the observation of no excess risk of non-
anogenital tumours among women in the case groups,
suggests that these findings are real.
Nonetheless, several biases that might have produced a
spurious result must be considered. First, we encountered a
moderate level of nonresponse. However, we have reason to426 K.J. SHERMAN et al.
believe that the observed association did not result from the
non-interviewed cases having an unusually low frequency of
prior or concurrent anogenital tumours. Using the Tumour
Registry records to identify prior or concurrent anogenital
cancers among all eligible cases of vulvar cancer, we found
that actually a slightly higher percentage of non-interviewed
than interviewed cases (23% vs 19%) had had such tumours.
Second, the excess number of anogenital tumours observed
in cases conceivably occurred as a result of more intensive
follow-up of women with cervical cancer leading to an
increased likelihood of detecting inconspicuous vulvar lesions
in these women. However, since women with invasive vulvar
cancer, a disease that rarely remains undetected for more
than a short period of time, reported a history of prior or
concurrent anogenital cancer more often than controls,
although less commonly than women with in situ vulvar
cancer, such a detection bias is unlikely to completely
account for the association in comparisons involving this
group of cases. In addition, the biopsy controls also had a
vulvar biopsy at reference date and thus, surveillance for the
case groups and this control group should be comparable.
The lower risk estimates we found when using the biopsy
controls as a comparison group could well have been due to
the differences in surveillance among the women in this
control group and the women in the random digit dialed
control group. On the other hand, some of the biopsy
controls may have been biopsied because they had a prior
history of conditions that can be precursors to vulvar cancer,
a possibility that, if true, would spuriously lower the risk
estimates.
As noted earlier, cases and controls did not differ
substantially in their accuracy of reporting a history of prior
or concurrent anogenital cancer; thus, recall bias could not
have explained the higher proportion of anogenital cancers
among the cases. Nor were differences in the frequency of
cervical screening among cases and controls responsible for
the positive association of anogenital cancers with vulvar
cancer, because the association remained after adjustment
for differences in screening history.
We believe that the most reasonable interpretation of these
observations is that the association is real. However, our
results do not allow us to discriminate between several
possibilities regarding its basis. One possibility is that the
association between vulvar cancer and a history of prior or
concurrent anogenital cancer reflects a common aetiology,
which is likely to be a sexually transmitted disease. Or, it
could be that these tumours are caused by different sexually
transmitted diseases, several of which often occur in the
same individual. Indeed, it is well known that people infected
with one sexually transmitted organism are more likely to be
at risk for other sexually transmitted infections. And,
evidence of exposure to many sexually transmitted organisms
has been observed in women with cervical cancer, including
syphilis, genital herpes, human papilloma virus, and
Chlamydia (Levin et al., 1942; Rojel, 1952; Melnick et al.,
1974; Kauffman & Adam, 1986; Durst et al., 1983; Syrjanen
et al., 1985; Schachter et al., 1982; Cardillo, 1985). These
same diseases also have been found more often in women
with vulvar cancer than would be expected in a similar
group of women without this disease (Franklin & Rutledge,
1974; Mabuchi et al., 1985; Schwartz & Naftolin, 1981;
Rueda-Leverone et al., 1987) and have been found in
patients with anal cancer more often than in controls (Gal et
al., 1987; Bogomoletz et al., 1985; Daling et al., 1987).
Recently, there has accumulated strong evidence to suggest
that human papilloma virus is one aetiology common to all
anogenital cancers. Human papilloma virus has been found
in tumour tissue from the cervix, vulva, vagina, and anus
(Okagaki, 1984; Durst et al., 1983; Syrjanen et al., 1985;
Rueda-Leverone et al., 1987; Gal et al., 1987; Winkler &
Richart, 1987). In addition, there have been several reports
of multicentric human papilloma virus infections in the same
individual (Sfameni et al., 1986; Walker et al., 1983;
Bergeron et al., 1987). Finally, there have been several
reports of finding the same type of human papilloma virus in
multiple anogenital cancers in the same individual (Weed et
al., 1983; McCance et al., 1985; Beckmann et al., 1988).
Genital herpes and smoking are two additional putative risk
factors that are found more often among cases with cervical
(Clarke et al., 1982; Brinton et al., 1986), anal (Daling et al.,
1987), and vulvar (Schwartz & Naftolin, 1981; Newcomb et
al., 1984) cancer than among controls. Whether herpes
simplex virus type 2, human papilloma virus, and smoking
are independent risk factors or whether they interact with
each other in the development of anogenital cancers remains
to be clarified.
This work was supported in part by Grant No. CA 35881 from the
National Cancer Institute.
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